

POST-MARKETING SURVEILLANCE SYSTEM, A CONTRIBUTION TO GLOBAL FOOD SAFETY

Ana Batalha,

Rue du Duc 64, 1150 Brussels

The interdependency of post-marketing surveillance, pharmacovigilance and food safety, highlights the need for properly funded risk based approach at state level - based on assessment, management and communication – to ensure the proper functioning of those systems.

The authorities with competency in post-marketing surveillance and food safety share a large amount of important common data on evaluation mechanisms as well as responsibilities to ensure timely decisions based on the legal framework to protect animal and public health in line with national legislation and the relevant international standards.

An overview of the evaluation of Veterinary Services in 25 countries performing these tasks, made by the OIE using the Performance of Veterinary Services (PVS) tool, shows that significant improvement is still needed at global level to implement the veterinary pharmacovigilance and residue monitoring systems.

Notification, collection, pooling, evaluation and decision making mechanisms, of all pharmacovigilance data, including adverse reactions in animals and humans when applying the medicines, the lack of efficacy in particular in the case of vaccines and antimicrobials and presence of its residues in food, are all important pillars of the system. The management of the system can be

enhanced by strong cross-border cooperation between the actors in the different technical areas, sharing responsibilities at regional and international level.

The post marketing surveillance system, including all the relevant data linked to quality, efficacy, safety and residues of the authorized products, will enhance the regulations and contribute to safer veterinary medicines in the market and improved protection of public health at global level.

REFERENCES

- F M Lortie, Postmarketing surveillance of adverse drug reactions: problems and solutions. *CMAJ*. Jul 1, 1986; 135(1): 27–32.
- Barnes J. Pharmacovigilance of herbal medicines : a UK perspective. *Drug Saf*. 2003;26(12):829-51.
- Borg JJ¹, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. *Drug Saf*. 2011 Mar 1;34(3):187-97.
- Bekkering GE¹, Kleijnen J. Procedures and methods of benefit assessments for medicines in Germany. *Eur J Health Econ*. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

Corresponding author E.mail : na.isabel.batalha@gmail.com